1357945-96-0

Basic information

• Product Name: 3-c]pyridin-3-aMine
• Synonyms: 7-bromo-1H-pyrazolo[4,3-c]pyridin-3-amine;1H-Pyrazolo[4,3-c]pyridin-3-amine, 7-bromo-
• CAS NO: 1357945-96-0
• Molecular Formula: C6H5BrN4
• Molecular Weight: 213.0347
• Mol File: 1357945-96-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-c]pyridin-3-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-c]pyridin-3-aMine(1357945-96-0)
• EPA Substance Registry System: 3-c]pyridin-3-aMine(1357945-96-0)

Safety Data

• Hazardous Substances Data: 1357945-96-0(Hazardous Substances Data)

Upstream product

• 870244-34-1 3,5-dibromopyridine-4-carbonitrile 

Relevant articles and documents

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.